The impact of stress systems and lifestyle on dyslipidemia and obesity in anxiety and depression

Psychoneuroendocrinology

Volumn 38, Issue 2, 2013, Pages 209-218

  Van Reedt Dortland, Arianne K B ^a   Vreeburg, Sophie A ^b   Giltay, Erik J ^a   Licht, Carmilla M M ^b   Vogelzangs, Nicole ^b   Van Veen, Tineke ^a   De Geus, Eco J C ^b,d   Penninx, Brenda W J H ^a,b,c   Zitman, Frans G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Anxiety; Autonomic nervous system; Depression; HPA axis; Inflammation; Lifestyle; Tricyclic antidepressants

Indexed keywords

C REACTIVE PROTEIN; LIPID; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ALCOHOL CONSUMPTION; ANXIETY DISORDER; ARTICLE; AUTONOMIC NERVOUS SYSTEM; DEPRESSION; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SMOKING; STRESS;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY; AUTONOMIC NERVOUS SYSTEM; C-REACTIVE PROTEIN; DEPRESSION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFLAMMATION; LIFE STYLE; LIPID METABOLISM; MALE; MIDDLE AGED; OBESITY; PITUITARY-ADRENAL SYSTEM; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS;

EID: 84872865273     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2012.05.017     Document Type: Article

References (72)

1. Akbaraly T.N., Kivimaki M., Brunner E.J., Chandola T., Marmot M.G., Singh-Manoux A., Ferrie J.E. Association between metabolic syndrome and depressive symptoms in middle-aged adults: results from the Whitehall II study. Diabetes Care 2009, 32:499-504.
2. Anagnostis P., Athyros V.G., Tziomalos K., Karagiannis A., Mikhailidis D.P. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J. Clin. Endocrinol. Metab. 2009, 94:2692-2701.
3. Bakhru A., Erlinger T.P. Smoking cessation and cardiovascular disease risk factors: results from the third national health and nutrition examination survey. PLoS Med. 2005, 2:e160.
4. Bankier B., Barajas J., Martinez-Rumayor A., Januzzi J.L. Association between anxiety and C-reactive protein levels in stable coronary heart disease patients. Psychosomatics 2009, 50:347-353.
5. Barden N., Reul J.M., Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?. Trends Neurosci. 1995, 18:6-11.
6. Bays H.E., Dujovne C.A., McGovern M.E., White T.E., Kashyap M.L., Hutcheson A.G., Crouse J.R. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor versus other cholesterol-modulating agents trial evaluation [ADVOCATE]). Am. J. Cardiol. 2003, 91:667-672.
7. Beck A.T., Epstein N., Brown G., Steer R.A. An inventory for measuring clinical anxiety: psychometric properties. J. Consult Clin. Psychol. 1988, 56:893-897.
8. Bjorntorp P., Rosmond R. The metabolic syndrome-a neuroendocrine disorder?. Br. J. Nutr. 2000, 83(Suppl. 1):S49-S57.
9. Bonnet F., Irving K., Terra J.L., Nony P., Berthezene F., Moulin P. Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease. Atherosclerosis 2005, 178:339-344.
10. Booth M. Assessment of physical activity: an international perspective. Res. Q. Exerc. Sport 2000, 71:S114-S120.
11. Bots S., Tijhuis M., Giampaoli S., Kromhout D., Nissinen A. Lifestyle- and diet-related factors in late-life depression-a 5-year follow-up of elderly European men: the FINE study. Int. J. Geriatr. Psychiatry 2008, 23:478-484.
12. Breslau N., Peterson E.L., Schultz L.R., Chilcoat H.D., Andreski P. Major depression and stages of smoking. Arch. Gen. Psychiatry 1998, 55:161-166.
13. Broussard J., Brady M.J. The impact of sleep disturbances on adipocyte fimction and lipid metabolism. Best. Pract. Res. Clin. Endocrinol. Metab. 2010, 24:763-773.
14. Brouwer J.P., Appelhof B.C., Hoogendijk W.J., Huyser J., Endert E., Zuketto C., Schene A.H., Tijssen J.G., van Dyck R., Wiersinga W.M., Fliers E. Thyroid and adrenal axis in major depression: a controlled study in outpatients. Eur. J. Endocrinol. 2005, 152:185-191.
15. Brunner E.J., Hemingway H., Walker B.R., Page M., Clarke P., Juneja M., Shipley M.J., Kumari M., Andrew R., Seckl J.R., Papadopoulos A., Checkley S., Rumley A., Lowe G.D., Stansfeld S.A., Marmot M.G. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 2002, 106:2659-2665.
16. Capuron L., Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol. Psychiatry 2004, 56:819-824.
17. Craig W.Y., Palomaki G.E., Haddow J.E. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ 1989, 298:784-788.
18. de Wit L.M., Fokkema M., van Straten A., Lamers F., Cuijpers P., Penninx B.W. Depressive and anxiety disorders and the association with obesity, physical, and social activities. Depress. Anxiety 2010, 27:1057-1065.
19. Donders A.R., van der Heijden G.J., Stijnen T., Moons K.G. Review: a gentle introduction to imputation of missing values. J. Clin. Epidemiol. 2006, 59:1087-1091.
20. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
21. Dunbar J.A., Reddy P., Davis-Lameloise N., Philpot B., Laatikainen T., Kilkkinen A., Bunker S.J., Best J.D., Vartiainen E., Kai L.S., Janus E.D. Depression: an important comorbidity with metabolic syndrome in a general population. Diabetes Care 2008, 31:2368-2373.
22. Edwards S., Clow A., Evans P., Hucklebridge F. Exploration of the awakening cortisol response in relation to diurnal cortisol secretory activity. Life Sci. 2001, 68:2093-2103.
23. Engum A. The role of depression and anxiety in onset of diabetes in a large population-based study. J. Psychosom. Res. 2007, 62:31-38.
24. Esteve E., Ricart W., Fernandez-Real J.M. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin. Nutr. 2005, 24:16-31.
25. Gangwisch J.E., Malaspina D., Babiss L.A., Opler M.G., Posner K., Shen S., Turner J.B., Zammit G.K., Ginsberg H.N. Short sleep duration as a risk factor for hypercholesterolemia: analyses of the National Longitudinal Study of Adolescent Health. Sleep 2010, 33:956-961.
26. Gil K., Radzillowicz P., Zdrojewski T., Pakalska-Korcala A., Chwojnicki K., Piwonski J., Ignaszewska-Wyrzykowska A., Zaluga L., Mielczarek M., Landowski J., Wyrzykowski B. Relationship between the prevalence of depressive symptoms and metabolic syndrome. Results of the SOPKARD Project. Kardiol. Pol. 2006, 64:464-469.
27. Gold P.W., Gabry K.E., Yasuda M.R., Chrousos G.P. Divergent endocrine abnormalities in melancholic and atypical depression: clinical and pathophysiologic implications. Endocrinol. Metab. Clin. N. Am. 2002, 31:37-62. vi.
28. Gravely-Witte S., Stewart D.E., Suskin N., Grace S.L. The association among depressive symptoms, smoking status and antidepressant use in cardiac outpatients. J. Behav. Med. 2009, 32:478-490.
29. Grundy S.M., Vega G.L., Yuan Z., Battisti W.P., Brady W.E., Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am. J. Cardiol. 2005, 95:462-468.
30. Hamer M., Batty G.D., Marmot M.G., Singh-Manoux A., Kivimaki M. Anti-depressant medication use and C-reactive protein: results from two population-based studies. Brain Behav. Immun. 2011, 25:168-173.
31. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23:477-501.
32. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71:171-186.
33. IDS Guide, 2008. IDS Guide at http://www.ids-qids.org/.
34. Kajantie E., Eriksson J., Osmond C., Wood P.J., Forsen T., Barker D.J., Phillips D.I. Size at birth, the metabolic syndrome and 24-h salivary cortisol profile. Clin. Endocrinol. (Oxf.) 2004, 60:201-207.
35. Katano S., Nakamura Y., Nakamura A., Murakami Y., Tanaka T., Takebayashi T., Okayama A., Miura K., Okamura T., Ueshima H. Relationship between sleep duration and clustering of metabolic syndrome diagnostic components. Diabetes Metab. Syndr. Obes. 2011, 4:119-125.
36. Kendler K.S., Neale M.C., MacLean C.J., Heath A.C., Eaves L.J., Kessler R.C. Smoking and major depression. A causal analysis. Arch. Gen. Psychiatry 1993, 50:36-43.
37. Koponen H., Jokelainen J., Keinanen-Kiukaanniemi S., Kumpusalo E., Vanhala M. Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study. J. Clin. Psychiatry 2008, 69:178-182.
38. Kubzansky L.D., Cole S.R., Kawachi I., Vokonas P., Sparrow D. Shared and unique contributions of anger, anxiety, and depression to coronary heart disease: a prospective study in the normative aging study. Ann. Behav. Med. 2006, 31:21-29.
39. Latour M.A., Patterson B.W., Kitchens R.T., Ostlund R.E., Hopkins D., Schonfeld G. Effects of alcohol and cholesterol feeding on lipoprotein metabolism and cholesterol absorption in rabbits. Arterioscler. Thromb. Vasc. Biol. 1999, 19:598-604.
40. Licht C.M., de Geus E.J., Zitman F.G., Hoogendijk W.J., van, Dyck R., Penninx B.W. Association between major depressive disorder and heart rate variability in the Netherlands study of depression and anxiety (NESDA). Arch. Gen. Psychiatry 2008, 65:1358-1367.
41. Licht C.M., de Geus E.J., Seldenrijk A., van Hout H.P., Zitman F.G., Van Dyck R., Penninx B.W. Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension 2009, 53:631-638.
42. Licht C.M., De Geus E.J., van Dyck R., Penninx B.W. Longitudinal evidence for unfavorable effects of antidepressants on heart rate variability. Biol. Psychiatry 2010, 68:861-868.
43. Licht C.M., Vreeburg S.A., van Reedt Dortland A.K.B., Giltay E.J., Hoogendijk W.J., de Rijk R.H., Vogelzangs N., Zitman F.G., de Geus E.J., Penninx B.W. Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities. J. Clin. Endocrinol. Metab 2010, 95:2458-2466.
44. Manthey L., Leeds C., Veen Giltay.E.J., van T., Vreeburg S.A., Penninx B.W.J.H., Zitman F.G. Antidepressant use and salivary cortisol in depressive and anxiety disorders. Eur. Neurol. 2011, 21:691-699.
45. Miettinen O.S., Cook E.F. Confounding: essence and detection. Am. J. Epidemiol. 1981, 114:593-603.
46. Miettola J., Niskanen L.K., Viinamaki H., Kumpusalo E. Metabolic syndrome is associated with self-perceived depression. Scand. J. Prim. Health Care 2008, 26:203-210.
47. NCEP, 2002. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. 106 ed., pp. 3143-3421.
48. O'Donnell K., Wardle J., Dantzer C., Steptoe A. Alcohol consumption and symptoms of depression in young adults from 20 countries. J. Stud. Alcohol 2006, 67:837-840.
49. Penninx B.W., Beekman A.T., Smit J.H., Zitman F.G., Nolen W.A., Spinhoven P., Cuijpers P., De Jong P.J., Van Marwijk H.W., Assendelft W.J., Van Der M.K., Verhaak P., Wensing M., De Graaf R., Hoogendijk W.J., Ormel J., Van Dyck R. The Netherlands study of depression and anxiety (NESDA): rationale, objectives and methods. Int. J. Methods Psychiatr. Res. 2008, 17:121-140.
50. Penninx B.W., Kritchevsky S.B., Yaffe K., Newman A.B., Simonsick E.M., Rubin S., Ferrucci L., Harris T., Pahor M. Inflammatory markers and depressed mood in older persons: results from the health, aging and body composition study. Biol. Psychiatry 2003, 54:566-572.
51. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J. Clin. Invest. 2003, 111:1805-1812.
52. Pizzi C., Manzoli L., Mancini S., Costa G.M. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. Eur. Heart J. 2008, 29:1110-1117.
53. Rajala M.W., Scherer P.E. Mini review: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003, 144:3765-3773.
54. Ray K.K., Cannon C.P., Braunwald E. Recent trials of lipid lowering. Int. J Clin. Pract. 2007, 61:1145-1159.
55. Rodgers B., Korten A.E., Jorm A.F., Jacomb P.A., Christensen H., Henderson A.S. Non-linear relationships in associations of depression and anxiety with alcohol use. Psychol. Med. 2000, 30:421-432.
56. Sanchez-Villegas A., gado-Rodriguez M., Alonso A., Schlatter J., Lahortiga F., Serra M.L., Martinez-Gonzalez M.A. Association of the Mediterranean dietary pattern with the incidence of depression: the Seguimiento Universidad de Navarra/University of Navarra follow-up (SUN) cohort. Arch. Gen. Psychiatry 2009, 66:1090-1098.
57. Skilton M.R., Moulin P., Terra J.L., Bonnet F. Associations between anxiety, depression, and the metabolic syndrome. Biol. Psychiatry 2007, 62:1251-1257.
58. Skogen J.C., Harvey S.B., Henderson M., Stordal E., Mykletun A. Anxiety and depression among abstainers and low-level alcohol consumers. The Nord-Trondelag Health Study. Addiction 2009, 104:1519-1529.
59. Tsujii S., Bray G.A. A beta-3 adrenergic agonist (BRL-37,344) decreases food intake. Physiol. Behav. 1998, 63:723-728.
60. Vaccarino V., McClure C., Johnson B.D., Sheps D.S., Bittner V., Rutledge T., Shaw L.J., Sopko G., Olson M.B., Krantz D.S., Parashar S., Marroquin O.C., Merz C.N. Depression, the metabolic syndrome and cardiovascular risk. Psychosom. Med. 2008, 70:40-48.
61. van Reedt Dortland A.K.B., Giltay E.J., van Veen T., Zitman F.G. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatr. Scand. 2010, 122:30-39.
62. van Reedt Dortland A.K.B., Giltay E.J., van Veen T., van Pelt J., Zitman F.G. Associations between serum lipids and major depressive disorder: results from the Netherlands Study of Depression and Anxiety (NESDA). J. Clin. Psychiatry 2010, 71:729-736.
63. Veen G., Giltay E.J., Derijk R.H., van V.I., van P.J., Zitman F.G. Salivary cortisol, serum lipids, and adiposity in patients with depressive and anxiety disorders. Metabolism 2009, 58:821-827.
64. Vogelzangs N., Suthers K., Ferrucci L., Simonsick E.M., Ble A., Schrager M., Bandinelli S., Lauretani F., Giannelli S.V., Penninx B.W. Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology 2007, 32:151-159.
65. Vogelzangs N., Seldenrijk A., Beekman A.T., van Hout H.P., de Jonge P., Penninx B.W. Cardiovascular disease in persons with depressive and anxiety disorders. J. Affect. Disord. 2010, 125:241-248.
66. Vogelzangs N., Duivis H.E., Beekman A.T.F., Kluft C., Neuteboom J., Hoogendijk W., Smit J.H., Jonge P.de, Penninx B.W.J.H. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Trans. Psychiatry 2012, e79. 10.1038/tp.2012.8.
67. Vreeburg S.A., Hoogendijk W.J., van Pelt J., Derijk R.H., Verhagen J.C., van D.R., Smit J.H., Zitman F.G., Penninx B.W. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch. Gen. Psychiatry 2009, 66:617-626.
68. Vreeburg S.A., Kruijtzer B.P., van Pelt J., van Dyck R., de Rijk R.H., Hoogendijk W.J., Smit J.H., Zitman F.G., Penninx B.W. Associations between sociodemographic, sampling and health factors and various salivary cortisol indicators in a large sample without psychopathology. Psychoneuroendocrinology 2009, 34:1109-1120.
69. Vreeburg S.A., Zitman F.G., van P.J., de Rijk R.H., Verhagen J.C., van Dyck R., Hoogendijk W.J., Smit J.H., Penninx B.W. Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom. Med. 2010, 72:340-347.
70. WHO, 2008. WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/.
71. Whooley M.A., de Jonge P., Vittinghoff E., Otte C., Moos R., Carney R.M., Ali S., Dowray S., Na B., Feldman M.D., Schiller N.B., Browner W.S. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 2008, 300:2379-2388.
72. Wolk R., Somers V.K. Sleep and the metabolic syndrome. Exp. Physiol. 2007, 92:67-78.